The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

Thu, 22nd Oct 2020 11:06

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 250 - LOSERS

----------

Shaftesbury, down 13%, and Capital & Counties, down 11%. Shaftesbury said it intends to raise GBP307 million via the issue of new shares to ensure financial flexibility to navigate the "unprecedented" challenges created by the Covid-19 pandemic. Current market capitalisation is GBP1.33 billion. Capital & Counties Properties said it will participate in the Shaftesbury fundraise by providing GBP65 million.

----------

Moneysupermarket, down 5.7%, the price comparison website firm said revenue dropped across all of its businesses in the third quarter, with the company blaming the "disruption" caused by the pandemic. In the three months to September 30, Moneysupermarket's total revenue dropped 16% year on year to GBP85.1 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Premier African Minerals up 19%. The southern Africa-focused miner said it has settled all amounts it owes to directors, employees and other creditors, amounting to GBP600,057 of shares. Along with the GBP1.1 million placing, completed on Wednesday, the company is now debt free.

----------

OPG Power Ventures, up 16%. The Indian power plant operator said revenue in the year ended March 31 rose 9.5% to GBP154.0 million from GBP140.6 million. Pretax profit slipped 14% to GBP14.5 million from GBP16.9 million.

----------

4D Pharma up 16% after it proposed a merger with special-purpose acquisition company Longevity Acquisition Corp. Longevity shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each - an 18% premium to its GBP0.932 closing price on Wednesday - GBP144.5 million altogether. 4D's current market capitalisation is GBP141.1 million. The enlarged company will also launch an American depositary receipts programme, eyeing a Nasdaq listing.

----------

Pendragon up 12%, the motor retailer said it delivered a "very strong" third quarter, with total revenue down 14% annually, but up 1.2% like-for-like. Underlying pretax profit surged to GBP27.3 million from GBP3.0 million a year earlier. Opts not to reinstate annual guidance, however.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Kibo Energy, down 12% after the Africa-focused energy firm posted a narrowed loss in the six months to June 30. Its pretax loss slimmed to GBP1.3 million from GBP1.8 million, though like last year, it generated no revenue. Noted that Covid-19 has caused delays to its project development targets.

----------

Thalassa Holdings, dropped 12% after a regulatory filing showed investor Lombard Odier Asset Management Ltd trimmed its stake in the British Virgin Islands-based investment holding company to 1.4% from 14% during a transaction on Wednesday.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jul 2020 14:39

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

Read more
6 Jul 2020 12:38

Next part of tumour trial begins for 4D Pharma

(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.

Read more
6 Jul 2020 10:17

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

Read more
2 Jul 2020 12:14

Patient enrolment begins for 4D's Covid therapy candidate

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.

Read more
2 Jul 2020 09:16

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

Read more
26 May 2020 10:06

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

Read more
11 May 2020 10:45

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

Read more
20 Apr 2020 11:08

4D Pharma receives expedited approval for coronavirus study

(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.

Read more
20 Apr 2020 10:30

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

Read more
17 Apr 2020 13:53

4D Pharma upbeat on key findings from Blautix study

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.

Read more
17 Apr 2020 10:14

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

Read more
18 Mar 2020 18:09

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

Read more
18 Feb 2020 18:44

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

Read more
18 Feb 2020 09:26

4D Pharma raising at least ?18m via placing and subscription

(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.

Read more
18 Feb 2020 09:03

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.